tiprankstipranks
Context Therapeutics, Inc. (DE:6K9)
NASDAQ:6K9
Germany Market
6K9
Context Therapeutics
RESEARCH TOOLSreports

Context Therapeutics (6K9) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

6K9 Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Context
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6K9 Stock 12 Month Forecast

Average Price Target

€5.45
▲(190.09% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Context Therapeutics in the last 3 months. The average price target is €5.45 with a high forecast of €6.89 and a low forecast of €4.31. The average price target represents a 190.09% change from the last price of €1.88.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","3":"€3","5":"€5","7":"€7","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.88887896,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.4536958433333345,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.305549350000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.31</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.38,2.726836843076923,3.073673686153846,3.4205105292307696,3.7673473723076922,4.114184215384616,4.461021058461538,4.807857901538462,5.1546947446153855,5.501531587692308,5.848368430769231,6.195205273846154,6.542042116923078,{"y":6.88887896,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.38,2.616438141794872,2.852876283589744,3.0893144253846154,3.3257525671794874,3.5621907089743594,3.798628850769231,4.0350669925641025,4.271505134358975,4.507943276153847,4.744381417948719,4.9808195597435905,5.217257701538463,{"y":5.4536958433333345,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.38,2.528119180769231,2.6762383615384615,2.8243575423076925,2.972476723076923,3.120595903846154,3.268715084615385,3.4168342653846158,3.5649534461538464,3.7130726269230774,3.8611918076923084,4.009310988461539,4.15743016923077,{"y":4.305549350000001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.464,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.515,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.595,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.675,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€6.89Average Price Target€5.45Lowest Price Target€4.31
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on DE:6K9
Biren Amin
Piper Sandler
Piper Sandler
€6.03
Buy
220.63%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Context Therapeutics (NASDAQ: CNTX), IDEAYA Biosciences (NASDAQ: IDYA) and Edgewise Therapeutics (NASDAQ: EWTX)
Maxim Group Analyst forecast on DE:6K9
Jason McCarthy
Maxim Group
Maxim Group
€4.31→€6.89
Buy
266.43%
Upside
Assigned
05/19/26
Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
William Blair Analyst forecast on DE:6K9
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
05/18/26
Analysts' Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)
LifeSci Capital Analyst forecast on DE:6K9
Charles Zhu
LifeSci Capital
LifeSci Capital
€5.17
Buy
174.82%
Upside
Reiterated
05/15/26
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
H.C. Wainwright Analyst forecast on DE:6K9
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
€4.31
Buy
129.02%
Upside
Reiterated
05/07/26
Context Therapeutics Maintained at Buy as Advancing Clinical Pipeline and Upcoming Catalysts Support Unchanged $5 Price Target
JonesTrading Analyst forecast on DE:6K9
Boris Peaker
JonesTrading
JonesTrading
€6.03
Buy
220.63%
Upside
Reiterated
05/06/26
Analysts Are Bullish on Top Healthcare Stocks: Trevi Therapeutics (TRVI), EyePoint Pharmaceuticals (EYPT)
Guggenheim Analyst forecast on DE:6K9
Paul Jeng
Guggenheim
Guggenheim
€4.31
Buy
129.02%
Upside
Reiterated
05/06/26
Context Therapeutics (CNTX) Gets a Buy from Guggenheim
Cantor Fitzgerald Analyst forecast on DE:6K9
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
10/02/25
Context Therapeutics initiated with an Overweight at Cantor FitzgeraldContext Therapeutics initiated with an Overweight at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on DE:6K9
Biren Amin
Piper Sandler
Piper Sandler
€6.03
Buy
220.63%
Upside
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Context Therapeutics (NASDAQ: CNTX), IDEAYA Biosciences (NASDAQ: IDYA) and Edgewise Therapeutics (NASDAQ: EWTX)
Maxim Group Analyst forecast on DE:6K9
Jason McCarthy
Maxim Group
Maxim Group
€4.31→€6.89
Buy
266.43%
Upside
Assigned
05/19/26
Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
William Blair Analyst forecast on DE:6K9
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
05/18/26
Analysts' Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)
LifeSci Capital Analyst forecast on DE:6K9
Charles Zhu
LifeSci Capital
LifeSci Capital
€5.17
Buy
174.82%
Upside
Reiterated
05/15/26
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
H.C. Wainwright Analyst forecast on DE:6K9
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
€4.31
Buy
129.02%
Upside
Reiterated
05/07/26
Context Therapeutics Maintained at Buy as Advancing Clinical Pipeline and Upcoming Catalysts Support Unchanged $5 Price Target
JonesTrading Analyst forecast on DE:6K9
Boris Peaker
JonesTrading
JonesTrading
€6.03
Buy
220.63%
Upside
Reiterated
05/06/26
Analysts Are Bullish on Top Healthcare Stocks: Trevi Therapeutics (TRVI), EyePoint Pharmaceuticals (EYPT)
Guggenheim Analyst forecast on DE:6K9
Paul Jeng
Guggenheim
Guggenheim
€4.31
Buy
129.02%
Upside
Reiterated
05/06/26
Context Therapeutics (CNTX) Gets a Buy from Guggenheim
Cantor Fitzgerald Analyst forecast on DE:6K9
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
10/02/25
Context Therapeutics initiated with an Overweight at Cantor FitzgeraldContext Therapeutics initiated with an Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Context Therapeutics

3 Months
Matt PhippsWilliam Blair
Success Rate
4/8 ratings generated profit
50%
Average Return
+19.16%
Copying Matt Phipps's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +19.16% per trade.
1 Year
Matt PhippsWilliam Blair
Success Rate
5/8 ratings generated profit
63%
Average Return
+83.59%
Copying Matt Phipps's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +83.59% per trade.
2 Years
Jason McCarthyMaxim Group
Success Rate
6/9 ratings generated profit
67%
Average Return
+63.59%
Copying Jason McCarthy's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +63.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6K9 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
5
8
11
18
15
Buy
0
1
2
4
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
9
13
22
18
In the current month, 6K9 has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6K9 average Analyst price target in the past 3 months is 5.45.
Each month's total comprises the sum of three months' worth of ratings.

6K9 Financial Forecast

6K9 Earnings Forecast

Next quarter’s earnings estimate for 6K9 is -€0.07 with a range of -€0.09 to -€0.03. The previous quarter’s EPS was -€0.08. 6K9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 6K9 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6K9 is -€0.07 with a range of -€0.09 to -€0.03. The previous quarter’s EPS was -€0.08. 6K9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 6K9 has Performed in-line its overall industry.
No data currently available

6K9 Sales Forecast

Next quarter’s sales forecast for 6K9 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 6K9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 6K9 has Performed in-line its overall industry.
Next quarter’s sales forecast for 6K9 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 6K9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 6K9 has Performed in-line its overall industry.

6K9 Stock Forecast FAQ

What is DE:6K9’s average 12-month price target, according to analysts?
Based on analyst ratings, Context Therapeutics, Inc.’s 12-month average price target is 5.45.
    What is DE:6K9’s upside potential, based on the analysts’ average price target?
    Context Therapeutics, Inc. has 190.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Context Therapeutics, Inc. a Buy, Sell or Hold?
          Context Therapeutics, Inc. has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Context Therapeutics, Inc.’s share price target?
            The average share price target for Context Therapeutics, Inc. is 5.45. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €6.89 ,and the lowest forecast is €4.31. The average share price target represents 190.09% Increase from the current price of €1.88.
              What do analysts say about Context Therapeutics, Inc.?
              Context Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of Context Therapeutics, Inc.?
                To buy shares of DE:6K9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.